Eledon Pharmaceuticals (NASDAQ: ELDN) is pioneering a potential breakthrough in immunosuppression therapy aimed at extending the longevity of transplanted organs and enhancing the overall health and quality of life for...
Closely held Longhorn Vaccines and Diagnostics is developing peptide vaccines and monoclonal antibodies aimed at preventing and reducing the global burden of medical conditions caused by key bacterial toxins, including...
Terns Pharmaceuticals (NASDAQ:TERN) is developing a portfolio of novel, oral small-molecule product candidates based on clinically validated mechanisms of action to address serious diseases including oncology and...
Closely held Tasman Therapeutics is shifting the treatment landscape for treatment-resistant depression (TRD) with its registered, proprietary formulation—a first-of-its-kind, oral extended-release ketamine tablet.
Arch Biopartners (TXSV:ARCH; QTCQB:ACHFF) is at the forefront of developing breakthrough therapies to combat acute kidney injury (AKI) and prevent organ damage. By targeting the dipeptidase-1 (DPEP1) inflammation...
MaaT Pharma (EURONEXT:MAAT) is at the forefront of developing the world’s first full-ecosystem approach to restoring microbiome symbiosis in oncology, improving cancer patient survival through innovative, fecal-derived...
Vivos Therapeutics (NASDAQ:VVOS) is developing and commercializing innovative diagnostic and treatment methods for adult and pediatric patients suffering from sleep-related breathing disorders, including severe...
Closely held Future Fields is spearheading the world’s first synthetic biology system with an innovative transgenic bug-based approach—leveraging fruit flies to combine genetic engineering with insect farming to unlock...
Closely-held Evergen, formerly RTI Surgical, is advancing innovative medical solutions across the cardiac, sports and orthopedics, plastic and reconstructive surgery, and neuro-spine clinical segments as the only...
Climb Bio (NASDAQ:CLYM) is advancing a pipeline of best-in-class, patient-tailored therapeutics to address the unmet needs of complex and clinically-diverse immune-mediated diseases.